Lopinavir pharmacokinetics in COVID-19 patients.
作者信息
Gregoire Matthieu, Le Turnier Paul, Gaborit Benjamin J, Veyrac Gwenaelle, Lecomte Raphaël, Boutoille David, Canet Emmanuel, Imbert Berthe-Marie, Bellouard Ronan, Raffi François
机构信息
Clinical Pharmacology Laboratory Department, Nantes University Hospital, Nantes, France.
UMR INSERM 1235, The enteric nervous system in gut and brain disorders, University of Nantes, Nantes, France.
出版信息
J Antimicrob Chemother. 2020 Sep 1;75(9):2702-2704. doi: 10.1093/jac/dkaa195.
Abstract
摘要
相似文献
1
Lopinavir pharmacokinetics in COVID-19 patients.洛匹那韦在新冠肺炎患者中的药代动力学。
J Antimicrob Chemother. 2020 Sep 1;75(9):2702-2704. doi: 10.1093/jac/dkaa195.
2
Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.洛匹那韦/利托那韦口服液治疗 ICU 机械通气 COVID-19 患者的药代动力学。
J Antimicrob Chemother. 2020 Sep 1;75(9):2657-2660. doi: 10.1093/jac/dkaa261.
3
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.在新冠肺炎患者中停用洛匹那韦/利托那韦：药物相互作用效应的持续时间。
J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086. doi: 10.1093/jac/dkaa253.
4
COVID-19 in a patient with pre-existing acute lymphoblastic leukaemia.一名患有既往急性淋巴细胞白血病患者的新型冠状病毒肺炎
Br J Haematol. 2020 Jul;190(1):e13-e15. doi: 10.1111/bjh.16799. Epub 2020 Jun 2.
5
Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).洛匹那韦和利托那韦在2019冠状病毒病（COVID-19）住院患者中的药代动力学
Ann Intern Med. 2020 Oct 20;173(8):670-672. doi: 10.7326/M20-1550. Epub 2020 May 12.
6
BET 1: Lopinavir-ritonavir and COVID-19.赌注1：洛匹那韦-利托那韦与2019冠状病毒病
Emerg Med J. 2020 Jul;37(7):450-451. doi: 10.1136/emermed-2020-210221.2.
7
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.SARS-CoV-2 全身炎症反应对洛匹那韦和羟氯喹血浆浓度的影响。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01177-20.
8
Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.利托那韦和洛匹那韦在一名感染新型冠状病毒肺炎患者中诱导红细胞凋亡。
Blood. 2020 Aug 13;136(7):915. doi: 10.1182/blood.2020006228.
9
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.五名重症新型冠状病毒肺炎患者接受了洛匹那韦/利托那韦、羟氯喹和干扰素β-1b三联疗法治疗。
Int J Antimicrob Agents. 2020 Aug;56(2):106052. doi: 10.1016/j.ijantimicag.2020.106052. Epub 2020 Jun 13.
10
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.
引用本文的文献
1
Advances and Challenges in Antiviral Development for Respiratory Viruses.呼吸道病毒抗病毒药物研发的进展与挑战
Pathogens. 2024 Dec 31;14(1):20. doi: 10.3390/pathogens14010020.
2
Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19.洛匹那韦/利托那韦与瑞德西韦在降低COVID-19患者病毒载量及病毒脱落持续时间方面的疗效相当。
Microorganisms. 2024 Aug 16;12(8):1696. doi: 10.3390/microorganisms12081696.
3
Pharmacomicrobiomics and Drug-Infection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy.药物微生物组学与药物-感染相互作用：共生菌、共生菌和病原菌对宿主药物治疗反应的影响。
Int J Mol Sci. 2023 Dec 4;24(23):17100. doi: 10.3390/ijms242317100.
4
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.卵巢癌治疗中的 Mirvetuximab soravtansine：药理学考虑的专家意见。
Cancer Chemother Pharmacol. 2024 Feb;93(2):89-105. doi: 10.1007/s00280-023-04575-y. Epub 2023 Aug 18.
5
SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染会使Vero E6细胞中临床相关药物代谢酶的表达以及人肺组织中膜转运蛋白的表达失调。
Front Pharmacol. 2023 Apr 27;14:1124693. doi: 10.3389/fphar.2023.1124693. eCollection 2023.
6
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.达芦那韦乙醇酸盐：将一种抗艾滋病毒药物用于新冠肺炎治疗的新用途。
Eur J Med Chem Rep. 2021 Dec;3:100013. doi: 10.1016/j.ejmcr.2021.100013. Epub 2021 Oct 22.
7
Coupling the Within-Host Process and Between-Host Transmission of COVID-19 Suggests Vaccination and School Closures are Critical.将 COVID-19 的宿主内过程和宿主间传播联系起来表明，接种疫苗和关闭学校至关重要。
Bull Math Biol. 2022 Dec 19;85(1):6. doi: 10.1007/s11538-022-01104-5.
8
The Role of CYP3A in Health and Disease.细胞色素P450 3A在健康与疾病中的作用
Biomedicines. 2022 Oct 24;10(11):2686. doi: 10.3390/biomedicines10112686.
9
COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics.新型冠状病毒肺炎疫苗与病毒：对药物代谢动力学和药物代谢的影响。
Drug Metab Dispos. 2023 Jan;51(1):130-141. doi: 10.1124/dmd.122.000934. Epub 2022 Oct 23.
10
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions.细胞因子释放综合征和/或前炎症细胞因子作为下调药物代谢和药物转运的潜在机制：不同临床条件下该药物-疾病相互作用的致害药物临床药代动力学的系统评价。
Clin Pharmacokinet. 2022 Nov;61(11):1519-1544. doi: 10.1007/s40262-022-01173-8. Epub 2022 Sep 5.
本文引用的文献
1
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.瑞德西韦、洛匹那韦、依米丁和高三尖杉酯碱在体外抑制 SARS-CoV-2 复制。
Antiviral Res. 2020 Jun;178:104786. doi: 10.1016/j.antiviral.2020.104786. Epub 2020 Apr 3.
2
Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography-tandem mass spectrometry and ultrafiltration methods.采用液相色谱-串联质谱法和超滤法测定血浆中洛匹那韦的总浓度和游离浓度。
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Aug 15;965:216-23. doi: 10.1016/j.jchromb.2014.06.034. Epub 2014 Jul 8.
3
Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.免疫激活导致α-1-酸性糖蛋白变化：对洛匹那韦总暴露量和游离洛匹那韦暴露量的影响。
J Clin Pharmacol. 2011 Nov;51(11):1539-48. doi: 10.1177/0091270010385118. Epub 2011 Jan 5.
4
Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.感染性和炎症性疾病对细胞色素P450介导的药物代谢及药代动力学的影响。
Clin Pharmacol Ther. 2009 Apr;85(4):434-8. doi: 10.1038/clpt.2008.302. Epub 2009 Feb 11.
5
Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient.一名HIV感染患者肺内洛匹那韦浓度的检测
AIDS. 2003 Jul 25;17(11):1710-1. doi: 10.1097/00002030-200307250-00022.
6
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.洛匹那韦血浆谷浓度的个体内变异性支持治疗药物监测。
AIDS. 2003 May 2;17(7):1107-8. doi: 10.1097/00002030-200305020-00029.
Zotero 插件